Ivermectin Treatment Prevents the Augmentation of the Cathelicidin Immune Pathway

[Guide]

"Overall, the results of this study suggest that ivermectin treatment prevents the augmentation of the cathelicidin immune pathway, which has a positive impact on the downstream inflammatory pathway (e.g., decreased IL-8, IL-6 and CCL2 secretion). These results suggest that ivermectin can prevent the inflammatory effects of rosacea triggered by abnormal LL-37 processing, through the inhibition of KLK5and CAMP gene expression in the epidermis."

Dermatol Ther (Heidelb). 2017 Jun; 7(2): 213–225.
Published online 2017 Feb 27. doi:  10.1007/s13555-017-0176-3
PMCID: PMC5453918
Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models
Séverine Thibaut de Ménonville,corresponding author Carine Rosignoli, Estelle Soares, Manon Roquet, Béatrice Bertino, Jean-Paul Chappuis, Claire Defoin-Platel/Chaussade, and David Piwnica

More on Cathelicidin

[Guide]

Topical IVM has shown to downregulate the proinflammatory genes IL-8, cathelicidin LL-37, HBD 3, TLR-4, and TNF-α in papulopustular rosacea along with its antiparasitic action against Demodex.

IVM 1% cream is now approved by US FDA for the treatment of inflammatory rosacea. IVM not only targets Demodex folliculorum but also reduces the inflammation associated with the condition. Results of a two-week controlled, investigator-blinded trials revealed that IVM 1% cream is superior to placebo in reducing inflammatory lesions in papulopustular rosacea, with near-complete treatment response, and improving patient satisfaction and quality of life.[54] In addition, IVM 1% cream was found to be better than metronidazole 0.75% cream for decreasing the inflammatory lesion count, reaching “clear” or “almost clear” response and patient satisfaction.[78] IVM is also well-tolerated and beneficial for the treatment of perioral dermatitis.

Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action

[Guide]

IVM has broad-spectrum in-vitro antiviral activity against many RNA and DNA viruses, including human immunodeficiency virus-1 (HIV-1), dengue virus (DENV), influenza, Venezuelan equine encephalitis virus (VEEV), a flavivirus, pseudorabies virus, and Zika virus.

In addition to controlling filariasis, the mass drug administration (MDA) of IVM has also had effects on limiting the spread of malaria.

Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action